Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371492 | 0.84 | BACE1 (0.44) | BACE1STK17BMAPT | |
| SCHEMBL14808535 | 0.81 | BACE1 (0.43) | BACE1 | |
| SCHEMBL15717226 | 0.76 | BACE1 (0.33) | BACE1MAPT | |
| SCHEMBL15448620 | 0.71 | BACE1 (0.43) | BACE1 | |
| SCHEMBL2370782 | 0.70 | BACE1 (0.54) | BACE1 | |
| SCHEMBL2372086 | 0.69 | BACE1 (0.54) | BACE1 | |
| SCHEMBL2371441 | 0.67 | BACE1 (0.52) | BACE1 | |
| SCHEMBL15468124 | 0.67 | BACE1 (0.52) | BACE1 | |
| SCHEMBL15468039 | 0.67 | BACE1 (0.30) | BACE1 | |
| SCHEMBL2371053 | 0.67 | BACE1 (0.49) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012446-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | BACE1 1/4885STK17B 1659/4885MAPT 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.